Abu Dhabi: Since its launch in October 2022, the Personalized Precision Medicine Program by Abu Dhabi’s Department of Health (DoH), in collaboration with strategic partners, has transformed Cancer Care in the region.
Tailored treatment plans have been provided to 256 Emirati cancer patients, with preventive measures extended to their families.
The program includes genetic screening for 47 genes, enabling personalized care for high-risk patients and family members with inherited cancer-related mutations.
To further expand its impact, 200 additional individuals from the Emirati Genome Program underwent screening for breast, ovarian, colorectal, and lung cancer risk, with tailored prevention plans provided to high-risk individuals.
Dr. Asma Ibrahim Al Mannaei of DoH emphasized the transformative potential of genomic technologies in addressing healthcare challenges and enhancing therapeutics. Al Mannaei noted plans to extend precision medicine beyond oncology to tackle other chronic diseases, reinforcing Abu Dhabi’s leadership in life sciences.
Dr. Stephen Grobmyer of Cleveland Clinic Abu Dhabi praised the initiative as a groundbreaking effort to enhance cancer prevention and treatment nationwide, leveraging cutting-edge resources and expertise to improve patient outcomes.
The program has significantly improved treatment precision, reduced adverse effects, and mitigated resistance, delivering impactful results. Recently, DoH issued germline testing guidelines for breast and ovarian cancer to advance diagnosis and prevention.
In partnership with Cleveland Clinic Abu Dhabi and G42 Healthcare, the initiative positions Abu Dhabi as a global hub for healthcare innovation, driving genomic advancements to improve cancer care and prevention strategies.